Business, energy, technology, markets and global industry news from Business News Today

VOXZOGO

PharmaDeviceNews VOXZOGO
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

BioMarin seeks FDA approval for Voxzogo in hypochondroplasia after Phase 3 success

BioMarin presents Voxzogo skull growth research and Phase 3 hypochondroplasia data. Examine clinical evidence, FDA reviews and 2027 prospects.

Read More
Representative image: Pediatric growth monitoring illustrates BridgeBio Pharma’s oral infigratinib FDA Priority Review for children with achondroplasia after positive Phase 3 results.
Pharma & Biotech

Oral infigratinib moves toward FDA decision after positive PROPEL 3 trial

FDA grants Priority Review to oral infigratinib after positive PROPEL 3 achondroplasia results, setting a February 4, 2027 decision.

Read More
Pharma & Biotech

VOXZOGO added 2.33 cm a year in Phase 3. Can BioMarin turn that growth signal into a new FDA indication?

BioMarin’s VOXZOGO met its Phase 3 hypochondroplasia endpoint with a 2.33 cm/year growth velocity benefit as an FDA filing moves forward.

Read More
Pharma & Biotech

Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?

Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More